Navigation Links
iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology
Date:4/11/2011

CHAMPAIGN, Ill., April 11, 2011 /PRNewswire/ -- iCyt Mission Technology, Inc. (iCyt), a wholly-owned subsidiary of Sony Corporation of America, today announced the introduction of its new line of 405nm-excited fluorochrome conjugated antibodies for flow cytometry. These new Brilliant Violet™ 421 products are part of the first commercial release of a novel, polymer-based fluorophore technology.

"This exciting new class of fluorescent probes will make significant contributions to the future of flow cytometry, by bringing new power and utility to the violet (405nm) laser," said Gary Durack, CEO of iCyt. "The new Brilliant Violet fluors offer dramatic improvements in brightness and signal-to-noise ratio over the current choices for the violet laser."  

In addition to being an order of magnitude brighter than traditional violet excited fluorochromes, this new dye offers greater sensitivity for resolving weakly expressed antigens, and requires less compensation for spectral overlap. Their compatibility with other popular fluorochromes and fluorescent protein combinations offers versatility that will further expand researchers' options for multi-color panels.

The initial iCyt portfolio of anti-mouse and anti-human conjugates have been optimized for use with iCyt's Eclipse™ analyzer and upcoming Synergy™ benchtop sorter, but are compatible with all major commercial flow cytometers equipped with a 405nm laser.

The new BV421 line will include an extensive antibody selection that combines consistent bright staining that is effective for surface and intracellular antigens, with simple, ready-to-use, low volume test size.  The new probes are fixation stable and compatible with standard staining buffers.  

iCyt intends to continually expand its new line of BV reagents, which complement its already broad portfolio of mouse and human monoclonal antibodies tailored for use in cell biology, immunology, cancer research, and stem cell research.

"iCyt and Sony are committed to leading the way in bringing innovative, new instrument and reagent technology combinations to market, that maximize performance and value for our customers," added Durack.

About iCyt:

iCyt supplies advanced flow cytometry analysis and sorting technology for use in life science research. Its products are marketed to private and public research institutions, pharmaceutical and biotechnology companies, and large medical centers. iCyt has received significant industry recognition for its line of multi-channel, high-speed cell sorting products. iCyt, a wholly owned subsidiary of Sony Corporation of America, is headquartered in Champaign, Illinois. For more information, visit www.i-cyt.com.

Synergy and Eclipse are trademarks of iCyt Mission Technology, Inc. Brilliant Violet and Brilliant Violet 421 are trademarks of Sirigen Ltd.


'/>"/>
SOURCE iCyt Mission Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products
2. Generex Unveils Strategic Development Plan
3. Sigma-Aldrich Unveils Dynamic New Web Presence
4. NABP Unveils Relaunch of AWARErx.org
5. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
6. Correction: New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
7. New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
8. Troy Healthcare, LLC Acquires Stopain® Brand; Unveils New Pain Relieving Gel Set to Hit Stores in Early 2011
9. Pepex™ Unveils Development of First All-In-One Blood Glucose Meter
10. eTransX Unveils Latest Version of Its eTX HEMI
11. ERT Unveils Full Range of ePRO Solutions Providing the Power of Choice for Clinical Trial Sponsors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)...   Zillion Group today announced the ... which specializes in live video consultation. Turning content, ... Zillion enables companies to realize the true potential ... control of their health. Zillion,s ... one-to-one, group and webcast scheduled or on-demand – ...
Breaking Medicine Technology:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... surgeon reveals that infants born with severe congenital diaphragmatic hernia have better survival ... born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):